Skip to main content
. 2021 Nov 3;12:751373. doi: 10.3389/fendo.2021.751373

Table 2.

Characteristics of PCOS group in the training and validation cohorts.

Training cohort Validation cohort p-Value
Patients 1,128 491
Female age (years) 28.90 ± 3.72 28.95 ± 3.83 0.809
Male age (years) 29.78 ± 4.24 29.98 ± 4.35 0.397
Female BMI (kg/m2) 24.41 ± 3.37 24.40 ± 3.28 0.962
Infertility duration (months) 47.51 ± 33.58 45.66 ± 33.26 0.307
AMH (ng/ml) 8.46 ± 4.32 8.60 ± 4.35 0.548
Basal FSH (mIU/ml) 5.80 ± 1.58 5.80 ± 1.49 0.947
Basal LH (mIU/ml) 10.18 ± 7.82 10.49 ± 7.44 0.463
Gonadotrophin duration (days) 14.65 ± 2.61 14.83 ± 2.77 0.204
Gonadotrophin dosage (IU) 2,174.58 ± 856.0 2,214.03 ± 915.26 0.404
Oocytes retrieved 19.17 ± 7.67 19.24 ± 7.77 0.857
Fertilization rate (%) 64.12 ± 16.71 62.97 ± 16.53 0.200
Cleavage rate (%) 98.70 ± 4.21 98.75 ± 3.63 0.810
Top day 3 embryo rate (%) 66.09 ± 24.70 64.43 ± 24.59 0.215
Blastulation rate (%) 53.30 ± 31.28 52.78 ± 30.20 0.753
High-quality blastulation rate (%) 18.53 ± 23.42 17.93 ± 21.87 0.628
Embryo utilization rate (%) 53.89 53.50 0.618
Average number of ET 1.57 ± 0.50 1.57 ± 0.50 0.979
Embryo implantation rate (%) 61.34 57.76 0.197
Clinical pregnancy rate (%) 76.79 73.84 0.331
Live birth rate (%) 58.39 58.42 0.993

PCOS, polycystic ovary syndrome; BMI, body mass index; AMH, anti-Mullerian hormone; FSH, follicle-stimulating hormone; LH, luteinizing hormone; ET, embryo transfer.